PFG
MYGN icon

Piershale Financial Group’s Myriad Genetics MYGN Stock Holding History

Piershale Financial Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-54,791
Closed -$2.13M – 169
2014
Q2 		$2.13M Sell
54,791
-21,398
-28% -$796K 1.74% 15
2014
Q1 		$2.6M Buy
+76,189
New +$2.36M 3.04% 20

Other funds holding MYGN

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Piershale Financial Group's MYGN Position: Q3 2014 in Review

Piershale Financial Group sold out of Myriad Genetics (MYGN) in Q3 2014, closing a stake of 54,791 shares — an estimated $2.13M sold.

Piershale Financial Group first reported a position in MYGN in Q1 2014 and held it in 2 quarters. The position peaked at $2.6M in Q1 2014. 275 funds tracked by Wall St. Rank hold MYGN as of Q3 2014.

  • Piershale Financial Group reported no remaining Myriad Genetics position as of Q3 2014 after selling out during the quarter.
  • Piershale Financial Group sold 54,791 Myriad Genetics shares in Q3 2014, an estimated $2.13M.
  • Piershale Financial Group first reported a position in Myriad Genetics in Q1 2014 and held it in 2 quarters.
  • Piershale Financial Group's Myriad Genetics position peaked at $2.6M in Q1 2014.
  • 275 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2014.

Based on Piershale Financial Group's 13F filing for Q3 2014, filed 21 Oct 2014.